The role of cation-exchange resins in hyperkalemia management

Hyperkalemia, characterized by elevated serum potassium levels, poses significant health risks, including life-threatening cardiac arrhythmias. The management of hyperkalemia has evolved, incorporating calcium polystyrene sulfonate (CPS) and newer agents such as sodium zirconium cyclosilicate (SZC) and patiromer alongside traditional treatments. This review provides a comprehensive examination of current management strategies for hyperkalemia, focusing on the comparative effectiveness, safety profiles, and patient preferences concerning CPS, SZC, and patiromer. Through an analysis of clinical trials, safety data, and guidelines, we highlight SZC's rapid action and favorable safety profile compared to CPS, which has been a standard treatment option for years. Additionally, the review explores patiromer, other emerging treatments, and future directions in hyperkalemia management, including the potential benefits of combination therapies and the role of personalized medicine. The findings suggest a shift toward newer potassium-binding agents in clinical practice, underscored by the need for individualized treatment approaches based on patient-specific factors. This article aims to guide clinicians in optimizing hyperkalemia management, ensuring effective, safe, and patient-centered care.